After recent the U.S. Food and Drug Adminiatrstion (FDA)'s approval of DN1406131's Investigational New Drug (IND) application in Jan 2018, Shanghai De Novo pharmatech Co., Ltd has received Clinical Trial

Application (CTA) approval on May 29, 2018 from the China Food and Drug Administration (CFDA) to conduct clinical trials in China with DN1406131.

DN1406131 is an oral and potent dual inhibitor of indoleamine 2,3-dioxygenase 1(IDO1) and tryptophan 2,3-dioxygenase 2(TDO2), for cancer immunotherapy.